<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00791830</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT no: 2008-001267-11</org_study_id>
    <nct_id>NCT00791830</nct_id>
  </id_info>
  <brief_title>Saving Residual Renal Function Among Haemodialysis Patients Receiving Irbesartan</brief_title>
  <acronym>SAFIR</acronym>
  <official_title>Saving Residual Renal Function Among Haemodialysis Patients Receiving Irbesartan - a Double Blind Randomised Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Angiotensin II receptor blockers (ARB) are known to preserve kidney function among patients
      with kidney diseases and reduced renal function, but not among haemodialysis patients.

      Haemodialysis patients often lose residual renal function after initiating dialysis leading
      to worsened quality of life, increased morbidity and mortality.

      In this study an ARB is investigated in a double blind, randomised, parallel group, placebo
      controlled manner to see, if this ARB can save residual renal function among haemodialysis
      patients. Potential cardiovascular benefits of the treatment are also addressed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Haemodialysis patients often lose residual renal function rather quickly after initiation of
      dialysis - average loss is 30 % per year. Loss of residual kidney function leads to
      deteriorating quality of life, more morbidity and a higher mortality. Many causes to this has
      been identified, but no one has - to my knowledge - addressed saving of residual renal
      function among haemodialysis patients so far.

      Hypothesis: Irbesartan can reduce loss of residual kidney function among haemodialysis
      patients and left ventricular hypertrophy and arterial stiffness is less pronounced after 1
      year of treatment.

      Methods: 80 patients are randomised to receive either irbesartan, an angiotensin II receptor
      blocker (ARB), or placebo for 1 year. Residual renal function will be estimated before and
      one-two weeks after initiating project medicine, in order to estimate the acute effect of ARB
      on residual renal function in this study population. Thereafter, glomerular filtration rate
      (GFR) and urine volume will be determined after 3, 6, 9 and 12 months giving a regression
      line for each patient. 8 dialysis units will be recruiting patients.

      Investigations:

        -  creatinine-urea-clearance by 24h urine collection

        -  applanation tonometry

        -  cardiac output

        -  echocardiography

        -  QoL questionnaire

        -  endocrinological and cardiovascular markers in blood and urine

      Perspectives: It is well-known that ceased urine production has a tremendous negative effect
      on the quality of life of haemodialysis patients. Lately it was shown that residual renal
      function has greater impact than dialysis dose on morbidity as well as mortality. Among
      peritoneal dialysis patients in Asia an angiotensin-converting enzyme inhibitors (ACEI) or an
      ARB saved residual renal function, but preservation of renal function has not been addressed
      in haemodialysis patients, and ACEI or ARB are only prescribed to roughly 15 % of these.

      If this study confirms our hypothesis the growing population of haemodialysis patients should
      be offered irbesartan.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in loss of residual kidney function.</measure>
    <time_frame>3, 6, 9 and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardio-vascular outcome assessed by applanation tonometry, echocardiography, Transonic measurements of cardiac output and markers in blood.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression to anuria</measure>
    <time_frame>3, 6, 9 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by a questionnaire: Kidney Disease Quality Of Life - Short Form (KDQOL-SF)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <arm_group>
    <arm_group_label>Irbesartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irbesartan</intervention_name>
    <description>Tablets, 300 mg * 1 daily, 1 year</description>
    <arm_group_label>Irbesartan</arm_group_label>
    <other_name>Aprovel</other_name>
    <other_name>Karvea</other_name>
    <other_name>Avapro</other_name>
    <other_name>CAS no: 138402-11-6</other_name>
    <other_name>ATC code: C09CA04</other_name>
    <other_name>PubChem: 3749</other_name>
    <other_name>Drugbank: APRD00413</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching irbesartan 150 mg</intervention_name>
    <description>Tablets, 300 mg * 1 daily, 1 year</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Haemodialysis patient

          -  Haemodialysis treatment for maximum 12 months

          -  &gt; 18 years old

          -  informed consent

          -  urine volume &gt; 300 ml / 24 hours

          -  contraception if fertile woman

        Exclusion Criteria:

          -  Systolic blood pressure &lt; 110 mm Hg

          -  Able to comprehend the aims of the project and follow instructions

          -  Allergy to irbesartan/ACE-inhibitors/ARBs

          -  Myocardial infarction or unstable angina pectoris during the last 3 months

          -  Ejection fraction &lt; 30 %

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bente Jespersen, MD, DrMedSc</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Nephrology, Aarhus University Hospital, Skejby, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erik Sloth, MD, DrMedSc</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Anaesthesiology and Intensive Care, Aarhus University Hospital, Skejby, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jens Kristian D Jensen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Nephrology, Aarhus University Hospital, Skejby, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Krista D Kj√¶rgaard, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Nephrology, Aarhus University Hospital, Skejby, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian D Peters, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Nephrology, Aarhus University Hospital, Skejby, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charlotte Strandhave, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology, Aalborg University Hospital, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ida N Tietze, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine, Region Hospital Viborg, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marija K Novosel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine, Region Hospital Fredericia, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Nephrology, Aarhus University, Aalborg</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Nephrology, Aarhus University Hospital, Skejby</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, Fredericia Hospital</name>
      <address>
        <city>Fredericia</city>
        <zip>7000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haemodialysis unit, Horsens Hospital</name>
      <address>
        <city>Horsens</city>
        <zip>8700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hemodialysis Unit, Randers Hospital</name>
      <address>
        <city>Randers</city>
        <zip>8600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medicine M, Viborg Hospital</name>
      <address>
        <city>Viborg</city>
        <zip>8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2008</study_first_submitted>
  <study_first_submitted_qc>November 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2008</study_first_posted>
  <last_update_submitted>January 7, 2013</last_update_submitted>
  <last_update_submitted_qc>January 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Residual renal function</keyword>
  <keyword>Haemodialysis</keyword>
  <keyword>Applanation tonometry</keyword>
  <keyword>Cardiac output</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Angiotensin II Type 1 Receptor Blockers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irbesartan</mesh_term>
    <mesh_term>Angiotensin II Type 1 Receptor Blockers</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

